Enanta Pharmaceuticals (NASDAQ:ENTA) Announces Quarterly Earnings Results

Enanta Pharmaceuticals (NASDAQ:ENTA) issued its earnings results on Monday. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.01, FiscalAI reports. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. The firm had revenue of $17.16 million during the quarter, compared to the consensus estimate of $17.03 million.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock traded up $0.13 on Monday, hitting $15.47. The company had a trading volume of 213,672 shares, compared to its average volume of 183,296. The firm has a market capitalization of $448.92 million, a P/E ratio of -4.83 and a beta of 1.01. Enanta Pharmaceuticals has a twelve month low of $5.03 and a twelve month high of $17.15. The stock has a 50-day moving average of $13.61 and a 200-day moving average of $13.42.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ENTA shares. Rodman & Renshaw started coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 26th. They issued a “buy” rating and a $20.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Monday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $20.29.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Deutsche Bank AG boosted its holdings in shares of Enanta Pharmaceuticals by 4.6% in the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 1,055 shares during the period. Public Employees Retirement System of Ohio boosted its holdings in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 1,100 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 8.3% in the third quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 1,383 shares during the period. Russell Investments Group Ltd. boosted its holdings in shares of Enanta Pharmaceuticals by 13.4% in the third quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 1,940 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.